Ellagic acid (EA), a naturally occurring plant polyphenol possesses broad chemoprotective properties. Dietary EA has been shown to reduce the incidence of A^-fluorenylacetamide-induced hepatocarcinogenesis in rats and iV-nitrosomethylbenzylamine (NMBA)-induced rat esophageal tumors. In this study changes in the expression and activities of specific rat hepatic and esophageal mucosal cytochromes P450 (P450) and phase II enzymes following dietary EA treatment were investigated. Liver and esophageal mucosal microsomes and cytosol were prepared from three groups of Fisher 344 rats which were fed an AIN-76 diet containing no EA or 0.4 or 4.0 g/kg EA for 23 days. In the liver total P450 content decreased by up to 25% and P450 2E1-catalyzed p-nitrophenol hydroxylation decreased by 15%. No changes were observed in P450 1A1, 2B1 or 3A1/2 expression or activities or cytochrome b 5 activity. P450 reductase activity decreased by up to 28%. Microsomal epoxide hydrolase (mEH) expression decreased by up to 85% after EA treatment, but mEH activities did not change. The hepatic phase II enzymes glutathione Stransferase (GST), NAD(P)H:quinone reductase [NAD-(P)H:QR] and UDP glucuronosyltransferase (UDPGT) activities increased by up to 26, 17 and 75% respectively. Assays for specific forms of GST indicated marked increases in the activities of isozymes 2-2 (190%), 4-4 (150%) and 5-5 (82%). In the rat esophageal mucosa only P450 1A1 could be detected by Western blot analysis and androstendione was the only P450 metabolite of testosterone detectable. However, there were no differences in the expression of P450 1A1, the formation of androstendione or NAD(P)H:QR activities between control and EA-fed rats in the esophagus. Although there was no significant decrease in overall GST activity, as measured with l-chloro-2,4-dinitrobenzene (CDNB), there was a significant decrease in the activity of the 2-2 isozyme (66% of control). In vitro incubations showed that EA at a concentration of 100 uJVI inhibited P450 2E1, 1A1 and 2B1 activities by 87, 55 and •Abbreviations: EA, ellagic acid; NMBA, /V-nitrosomethylbenzylamine; P450, cytochrome P450; 3-MC, 3-methylcholanthrene; IQ, 2-amino-3-methylimidazole[4,5-/|quinoline; DMSO, dimethylsulfoxide; GST, glutathione Stransferase; NAD(P)H:QR, NAD(P)H:quinone reductase; PNP, p-nitrophenol; CDNB, l-chloro-2,4-dinitrobenzene; BNF, p"-napthoflavone; PB, pnenobarbital; BCA, bicinchoninic acid; KPi, potassium phosphate; ECL, enhanced chemiluminescence; mEH, microsomal epoxide hydrolase; EROD, ethoxyresorufin dealkylase; PROD, pentoxyresorufin dealkylase; UDPGT, UDP glucuronosyllransferase; MI, metabolic intermediate.
Introduction
Ellagic acid (EA*) is a naturally occurring plant polyphenol, present in high concentrations in various fruits and nuts regularly consumed by humans (1). EA has been shown to possess numerous anticarcinogenic and antimutagenic properties towards a variety of different carcinogens, including nitrosamines, azoxymethane, mycotoxins and polycyclic aromatic hydrocarbons (2-7). EA also reduces the incidence of N-2-fluorenylacetamide-induced carcinogenesis in rats (8) and /V-nitrosomethylbenzylamine (NMBA)-induced tumors in the rat esophagus (9, 10) . Dietary administration of 400 p.p.m. ellagic acid for 16 weeks inhibited the incidence of hepatocellular neoplasms induced in rats by A'-2-fluorenylacetamide by 70% (from 100 to 30%) (8) . When administered orally to rats in a AIN-76 diet at concentrations of 0.4 and 4.0 g/kg EA produced a significant decrease (21-60%) in the average number of NMBA-induced esophageal tumors after 20-27 weeks (9, 10) . EA also decreased the number of esophageal preneoplastic and neoplastic lesions induced by NMBA (9, 10) .
Several mechanisms have been proposed to explain the broad antimutagenic and anticarcinogenic effects of EA (4, (11) (12) (13) (14) (15) (16) . One of the mechanisms proposed involves inhibition of cytochrome P450 enzymes (P450) (11). EA has been shown to lower total P450 content in rat hepatic (11, 17, 18) , lung (11) and esophageal microsomes (18) . It has also been shown to inhibit the bioactivation of procarcinogens which are metabolized by the P450 1A family, including benzo[a]pyrene, 3-methylcholanthrene (3-MC) and the food mutagen 2-amino-3-methylimidazole [4,5-/] quinoline (IQ) (2, 15, 17, (19) (20) (21) (22) . Barch and Fox (18) showed that dietary EA significantly reduced total esophageal and hepatic P450 levels and significantly reduced the esophageal microsomal metabolism of NMBA. Subsequent studies in vivo by Barch and Fox (14) demonstrated that dietary EA significantly reduced NMBA metabolic activation and DNA alkylation in the esophagus. Wilson et al. showed that EA [dissolved in dimethylsulfoxide (DMSO)] inhibited P450 2E1-catalyzed p-nitrophenol hydroxylation (23) .
Another mechanism proposed for the broad chemoprotective effects of EA involves induction of glutathione S-transferase (GST) activity in the liver (2, 11) . Majid etal. also demonstrated that dietary administration of EA to mice increased the levels of reduced glutathione and glutathione reductase in liver (13) .
The purpose of this study was to identify any changes in specific rat hepatic and esophageal mucosal P450s and phase II enzyme activities and/or expression following dietary treatment with EA. First, it has not yet been determined whether EA is specific in its inhibitory effects on P450 enzymes. Das et al. suggested that EA treatment may alter the composition of cytochrome P450 isozymes in mice (11). However, Aryton et al. suggested that EA is a non-selective inactivator of P450s (17). Second, NMBA is bioactivated by P450 enzyme(s) in rat esophageal mucosa (24) . Barch and Fox (18) found that dietary EA decreased the total amount of NMBA metabolism in the rat esophagus. However, it was not determined if the reduction in esophageal microsomal metabolism of NMBA following dietary administration of EA was due to a decrease in the concentration of a specific P450 form or to inhibition of esophageal P450 activity. Third, although earlier studies had reported an inhibitory effect of EA on P450 2E1 activity (23), the EA was dissolved in DMSO, which has been shown to be a competitive inhibitor of P450 2E1 activity (25) and appropriate control studies had not been performed. Fourth, the mechanism of inhibition of P450 enzymes by EA has not been determined. Finally, the effect of EA on the phase II enzymes GST and NAD(P)H:quinone reductase [NAD(P)H: QR] in the rat esophageal mucosa had not been investigated.
In this study the effects of dietary EA on the in vivo expression of specific forms of P450 and selected phase II enzymes in rat liver and esophageal mucosa and its in vitro effects as an inhibitor of the activities of several P450 forms were examined.
Materials and methods
Chemicals EA,/>-nitrophenol (PNP), erythromycin, l-chloro-2,4-dinitrobenzene (CDNB), undine diphosphoglucuronic acid triammonium salt, nicotinamide adenine dinucleotide, flavin adenine dinuclcotide, p^-napthoflavone (BNF), phenobarbital (PB), testosterone, 14a-OH testosterone, llpVOH testosterone, 2,6-dichloroindophenol, dicumarol [3,3'- 
Animal care and study design
Male Fischer 344 rats (5-6 weeks old) were purchased from Harlan Sprague Dawley Inc. (Indianapolis, IN)-The animals were quarantined for 2 weeks and then divided into three groups. Group 1 consisted of 54 rats fed an AIN-76 modified diet (no. 110107; Dyets Inc.) for 23 days; group 2 consisted of 51 rats fed the AIN-76 diet containing 0.4 g/kg EA for 23 days; group 3 consisted of 51 rats fed the AIN-76 diet containing 4.0 g/kg EA for 23 days.
Preparation of microsomes
Harvesting of tissues. Fasted rats were sacrificed by COj asphyxiation and the livers and esophagi were immediately excised. Esophagi were harvested from each rat and livers were harvested from six randomly selected rats per treatment group. A total of 153 esophagi and 18 livers were collected. The tissues were rinsed in ice-cold KC1 solution and frozen in dry ice after harvesting.
Livers. Rat livers from each group were pooled and homogenized in a Waring blender in 100 mM potassium phosphate (KPi) buffer, pH 7.4, containing 150 mM KG and 1 mM EDTA. The homogenate was centrifuged in a Sorvall RC2-B centrifuge at 16 270 g for 35 min. The supernatant was filtered through four layers of cheesecloth and the pellet was discarded. The supernatant was ultracentrifuged at 100 000 g for 75 min and the pellet was resuspended in 100 mM sodium pyrophosphate, I mM EDTA, pH 7.4, using a Potter-Elvehjem homogemzer and rccentrifuged at 100 000 g for 75 min. The supernatant (cytosol) was saved and stored at -70°C. The pellet was then suspended in 100 mM KPi, 1 mM EDTA, 20% sucrose, pH 7.4 buffer, and stored at -70°C.
Esophagi. The esophagi were nnsed in ice-cold KCI solution after harvesting. The esophageal mucosae were then mechanically stripped off the submucosae and any muscular tissues. The mucosae were then slit longitudinally and frozen in dry ice. After the esophageal mucosae were harvested from all rats they were transferred from dry ice into ice-cold 0.15 M KCI w/EDTA. The mucosae were blotted and weighed, and to each gram of mucosa was added 4.5 ml homogenizing buffer (150 mM KCI, 10 mM KPi, 0.5 mM EDTA). The tissues were then homogenized with a teflon-glass homogenizer and the homogenate centrifuged at 9000 g for 30 min at 0°C. The supernatant was then carefully removed and saved, the pellet discarded and the supernatant centrifuged at 105 000 g for 90 min at 0°C. The resulting supernatant (cytosol) was removed and stored at -70°C. The pellet was resuspended in 0.25 M sucrose buffer (0.5 ml/g tissue) and the microsomes stored at -70°C.
Quanlitation of total cytochrome P450
The total P450 content of the rat hepatic microsomes was determined using the spectral method of Omura and Sato (26) . The total P450 content of the esophageal microsomes could not be determined since the P450 level in the esophageal microsomes was below the detection limits of the spectral assay.
The P450 specific contents of the hepatic microsomes were 0.56, 0.42 and 0.47 nmol P450/mg protein respectively for control and 0.4 and 4.0 g/kg EAtreated animals (Table I) .
Electrophoresis and Western blot analysis
The effect of EA on expression of specific rat hepatic and esophageal mucosal cytochrome P450 forms was determined by immunoblot analysis. SDS gel electrophoresis of rat hepatic and esophageal mucosal microsomes was performed using 7.5% acrylamide gels according to the method of Laemmli (27) . Following electrophoresis the proteins were electroblotted onto a nitrocellulose membrane and blocked for 1 h with a 5% solution of dried milk powder. The membrane was immersed in the antibody solution either for 4 h or overnight (depending on the antibody) and then for 1 h in horseradish peroxidase-protein A conjugate solution (BioRad). The antibody-antigen complex was visualized using the enhanced chemiluminescence (ECL) method (Amersham). Western blots were performed using polyclonal antibodies raised against rabbit anti-rat cytochrome P450 1A1 (a gift from Dr Henry Strobel, University of Texas Medical School, Houston, TX), 2B1 (prepared as described previously; 28), 3A1/2 (a gift from Dr Fred Guengerich, Vanderbilt University), sheep anti-rabbit P450 2EI (a gift from Dr Dennis Koop, University of Oregon Health Science Center), P450 reductase (prepared as described previously) (29) and rabbit anti-rat hepatic microsomal epoxide hydrolase (mEH) (a gift from Drs Sang G.Kim and Raymond Novak, Wayne State University). Silver staining was performed as described by Wray et al. (30) . Densitometric analyses of the immunoblots were performed using the AMBIS™ Radioanalytic Imaging System and the AMBIS QuantProbe™ Software version 3.0 from AMBIS Inc. (San Diego, CA).
Protein determination
Protein concentrations of the rat hepatic samples were determined by the method of Lowry et al. (31) . The protein concentrations of the esophageal microsomes and cytosols were determined by the BCA assay (32), since reliable estimates of protein concentration of these microsomes were unobtainable using the Lowry method.
P450 enzyme activity assays
The effect of ellagic acid on enzyme activities associated with specific rat hepatic P450s was studied by assaying ethoxyresorufin dealkylation (EROD) (33) . pentoxyresorufin dealkylation (PROD) (34), PNP hydroxylation (35), eryihromycin jV-demethylation (36) and testosterone hydroxylation (using 14a-OH testosterone as an internal standard for the hepatic microsomes) (37) . The testosterone hydroxylation assay was also performed on the esophageal mucosal microsomes, using I lpVOH testosterone as an internal standard.
Phase II engine assays
Total GST and NAD(P)H:QR activities in rat liver and esophageal mucosal cytosol were assayed as described by Habig et al. (38) and Benson et al. (39) respectively. The effect of EA on enzyme activities associated with specific Rats were fed EA in the diet and microsomes were prepared as described in Materials and methods. P450 levels and enzyme activities were determined as described in Materials and methods. "Data are expressed as mean ± SD (n = 3 for all assays GST isozymes was studied by using substrates and inhibitors specific for the six basic GST activities in rat liver (40) (41) (42) . UDP glucuronosyltransferase (UDPGT) activity was assayed only in rat liver microsomes, since sufficient quantities of esophageal microsomes were not available for these assays.
UDPGT activity was assayed as described by Burchell and Weatherill (43) . Microsomal mEH activity was assayed as described by Guenthner et al., with slight modifications (44) .
Determination of cytochrome P450 reductase and cytochrome b$
Cytochrome b 5 concentrations in microsomes from control and EA-fed rats were determined as described by Levin et al. (45) . Cytochrome P450 reductase activity was determined as described by Phillips and Langdon (46) .
EA inhibition studies of specific P450 isozyme activities in vitro
EA was dissolved in buffer just prior to the incubations. The EA solution (1 mM) in 50 mM KPi buffer (pH either 6.8 or 7.4, depending on the assay performed) was filtered through a 0.5 |im Millipore filter, yielding a clear filtrate. The pH of the buffer did not change with addition of EA. The absorbance spectrum of the filtrate was determined from 200 to 600 nm using a Uvikon 930 spectrophotometer, and the EA concentration calculated using an extinction coefficient of S.SlXlO^/M/cm for the absorbance observed at 360 nm (47) . The appropriate amount of the EA solution was then added to the incubation mixture to give the desired final concentration. The effect of EA in vitro on rat hepatic P450 activities was examined by incubating EA (100 uM) with the microsomes indicated in enzyme assays thought to be specific for the different forms of P450. The assays used and the forms were: EROD (1A1) activity, using hepatic microsomes from BNFtreated rats (80 mg/kg i.p. for 4 days); PROD (2B1) and erythromycin Ndemethylation (3AI/2) activities, using hepatic microsomes from PB-treated rats (0.1% in drinking water for 12 days); PNP hydroxylation (2E1) activity, using hepatic microsomes from acetone-treated rats (1.0% in drinking water for 7 days). The effect of EA in vitro on rat hepatic P450 reductase activity was examined by incubating EA (100 |iM), dissolved in DMSO, with PBinduced microsomes in the assay described by Phillips and Langdon (46) , DMSO added to PB-induced microsomes without EA served as controls. The specific P450 contents of the microsomes were 1.44, 2.54 and 0.97 nmol/mg protein for BNF-, PB-and acetone-treated rats respectively.
Determination of inhibition constants (K t ) for EA
The K, of EA for the inhibition of EROD activity (1A1) was determined using hepatic microsomes from BNF-treated rats (0.1 nmol P450/reaction) and the standard EROD assay procedure (33) . Five concentrations of ethoxyresorufin were used, 0.1, 0.3, 0.5, 0.7 and 0.9 \iM, and the concentrations of EA used were 0, 50 and 100 |XM. The K x value was determined from double reciprocal plots of enzyme activity versus substrate concentration (48) . The K, of EA for inhibition of PNP hydroxylation activity (2E1) was determined using hepatic microsomes from acetone-treated rats (0.1 nmol P45Q/reaction). Five concentrations of PNP were used, 20, 60, 100, 140 and 180 jlM, and the concentrations of EA used were 0, 30 and 70 |iM. The K\ value was determined from double reciprocal plots of enzyme activity versus substrate concentration (48) .
Metabolic intermediate (Ml)-hcme complex formation studies
These experiments were performed to determine if EA inhibited P450 via the metabolism-dependent formation of an inactive metabolic intermediate (MI)-heme complex intermediate with P45O (49) . The procedure was similar to that used to dissociate troleandomycin from rat liver microsomes (49) .
Binding spectra
Hepatic microsomes from BNF-or acetone-treated rats were diluted to 1 mg/ ml in 50 mM KPi buffer, pH 7.4 (containing 20% glycerol), the solutions divided into tandem cuvettes and the baselines recorded. EA in concentrations ranging from 0 to 300 (iM was added to the microsomal and buffer compartments of sample and reference cuvettes respectively and incubated at 25°C for 5 min. The samples were then scanned repeatedly from 360 to 660 nm and the difference spectra were recorded using a Uvikon 930 spectrophotometer.
Metabolism of EA by liver microsomal P450
To determine if EA was a substrate for P45O, EA (400 nM) was incubated with hepatic microsomes (2 nmol of P450/reaction) from non-induced or BNF-, acetone-or PB-treated rats in 50 mM KPi buffer, pH 7.4, in a final volume of 1 ml. NADPH (1 mM) was added to initiate the reaction and samples were incubated at 37°C for 10 min. Reactions were terminated by addition of 3 ml ethyl acetate. Test tubes were vortexed, placed on ice for 5 min and centrifuged at 800 g for 15 min. The organic phase was removed, evaporated with compressed air and the residue dissolved in 100 (il methanol. Metabolite formation from EA was examined by HPLC analysis, using the HPLC method descnbed by Boukharts et al. (6) . Table I , the P450 specific contents of the hepatic microsomes of the EA-fed rats were decreased by 16-25% from those of control rats. For the P450 catalytic activities of the hepatic microsomes from control and EA-fed rats the only statistically significant change in activities was seen for P450 2E1 -catalyzed PNP hydroxylation (Table I) . Although the decrease in PNP hydroxylation activity after EA treatment was small (-15%), it was statistically significant (P < 0.05). The P450 reductase activities also were decreased by up to 29% (Table I) . No changes were observed in the activities of the other P450 forms tested nor in the levels of cytochrome by Testosterone hydroxylation activity, a general assay which can be used to monitor several forms of P450, showed no significant differences between liver microsomes of control and EA-fed rats (data not shown). Androstendione was readily measurable as the only observable metabolite of testosterone formed by esophageal mucosal microsomes, however, there were no statistically significant differences between control and EA-fed rats (data not shown).
Results

As shown in
SDS-PAGE of the rat hepatic microsomes showed no significant differences in the banding patterns and apparent densities in the P450 region between the control and EA-fed groups when proteins were detected using either Coomasie or silver staining (data not shown). Western blot analysis of rat hepatic microsomes from control and EA-fed rats using antibodies raised against P450 1A1, 2B1, 2E1 and 2A1/2 or P450 reductase showed no significant differences between controls and animals treated with EA (data not shown). In contrast, Western blotting of rat hepatic microsomes using an antibody raised against rat liver mEH showed a significant decrease in the levels of mEH in the EA-treated animals ( Figure 1) . Densitometry of the bands in Figure 1 indicated an 85% decrease in mEH in animals exposed to 0.4/kg EA (data not shown).
SDS-PAGE of the rat esophageal microsomes showed no significant differences in the banding patterns and apparent densities in the P450 region between control and EA-fed groups when proteins were detected by Coomasie or silver staining. A protein band having the same mobility as P450 1A1 was observed in both control and treated samples. Western blot analysis of the rat esophageal mucosal microsomes confirmed that detectable levels of P450 1A1 were present in esophageal mucosal microsomes from both control and EAfed (4.0 g/kg) rats, although no significant differences in the levels of P450 1 Al were observed after EA treatment ( Figure  2 ). P450 2B1, 2E1 and 3A1/2 could not be detected in rat esophageal mucosal microsomes by immunoblotting (data not shown).
The effects of EA (100 \iM) as an inhibitor of specific rat liver microsomal P450 and P450 reductase activities in vitro was investigated. EA caused significant inhibtion of P450 1A1-catalyzed EROD activity (50%), P450 2E1-catalyzed PNP hydroxylation (87%) and P450 2B1-catalyzed PROD activity (18%). However, EA had no effect in vitro on P450 3A1/2-catalyzed erythromycin N-demethylase activity and only a small inhibitory effect on P450 reductase activity (11%). In order to further characterize the inhibition of P450 catalytic activity by EA studies were performed in which the concentration of the P450 substrate in the assay mixture was systematic- ally varied while the concentration of EA was maintained constant and the initial rates for product formation were determined. This was done using two different concentrations of EA with each of the substrates showing significant inhibition (EROD and PNP). Double reciprocal plots of the data for inhibition of P450 1A1-catalyzed EROD and P450 2E1-catalyzed PNP hydroxylation activities by EA are shown in Figures 3 and 4 respectively. As shown in Figure 3 , the inhibition of EROD activity by EA appears to be noncompetitive and a K, of ~55 (iM was determined. As shown in Figure 4 , the inhibition of PNP hydroxylation by EA also appears to be non-competitive and a K t of -14 (iM was determined. In order to investigate the possible basis for the significant (up to 25%) decrease in spectrally observable P450 without a corresponding decrease in P450 detectable by Western blotting we investigated the possibility that EA forms an MI-heme complex with P450. However, the lack of spectral change in the Soret region following addition of potassium ferricyanide to microsomes from EA-treated rats (data not shown) ruled out the formation of a P450 MI complex with EA. In addition, EA did not exhibit either type I or II binding spectra with P450 1A1-or 2E1-enriched microsomes at concentrations of EA as high as 300 ^M (data not shown). Finally, EA was not metabolized to any significant extent by microsomes from BNF-pretreated (lAl-enriched) or acetone-pretreated (2E1-enriched) rats (data not shown).
The effects of dietary EA on the catalytic activities of selected phase II enzymes in rat liver and esophageal mucosa were also investigated. As shown in Table II , increases of ~26, 17 and 75% were observed in hepatic GST, NAD(P)H:QR and UDPGT activities respectively. Hepatic mEH activities did not change after dietary EA treatment. As can be seen in Table II , however, EA had no significant effect on the activities of GST or NAD(P)H:QR in rat esophageal mucosa. In order to gain a better understanding of the effect of EA on GST we investigated the changes in the activities of several specific GST isozymes in response to EA treatment. As shown in Table HI , significant increases in isozymes 2-2 (190%), 4-4 (150%) and 5-5 (82%) were seen in the liver. In the esophagus there was a slight (66% of control), but significant, decrease in GST 2-2 activity. inhibit NMBA-induced tumors in rat liver (8) and esophagus (9, 10) . Several different mechanisms have been proposed to explain the chemoprotective effects of EA (4, (11) (12) (13) (14) (15) (16) . The purpose of this study was to examine in detail the effects of dietary EA on specific forms of P450 and also on selected phase II enzymes in rat liver and esophageal mucosa.
In this study dietary EA resulted in a decrease in total hepatic cytochrome P450 of up to 25%. This is in agreement with earlier reports (11,17,18) . However, this decrease did not appear to be dose-dependent for the two concentrations of EA (0.4 and 4.0 g/kg) used, which may be attributable to the fact that both concentrations were in excess of the maximum amount required to suppress P450 or to the variable oral absorption of EA (50). The only statistically significant decrease in any of the individual hepatic P450 enzyme activities assayed was for PNP hydroxylase, presumably due to a decrease in P450 2E1. P450 2E1 in rats and humans is the principle enzyme for the bioactivation of a variety of low molecular weight suspect carcinogens, such as benzene, styrene and vinyl chloride, as well as nitrosamine carcinogens such as /V-nitrosodimethylamine (51). Das et al. demonstrated earlier that hepatic and lung aryl hydrocarbon hydroxylase and 7-ethoxycoumarin O-deethylase activities (markers for P450 1A1) decreased in BALB/C mice after chronic administration of EA in drinking water for 16 weeks or acute i.p. administration of EA for 5 days (11). In this study dietary administration of EA over 23 days did not affect rat hepatic ethoxyresorufin dealkylase activity, an assay highly specific for P450 1 Al (33) .
The most marked effects of EA on P450 activities were seen in vitro. These results suggest several interesting aspects with respect to the effects of EA on various forms of P450. First, EA appears to be a strong inhibitor of P450 2E1 and P450 1A1, two forms which are important in the bioactivation of a variety of suspect and known procarcinogens in rats and humans (51) . P450 2El-catalyzed PNP hydroxylation was inhibited 87% by 100 uM EA. Although inhibition of PNP hydroxylation by EA has previously been reported (23) , those studies were done using EA dissolved in DMSO, a potent inhibitor of 2E1 (25) . Our results conclusively demonstrate that the inhibition in vitro is due to EA rather than DMSO. These studies also show that EA exhibits a differential inhibition of P450 isozymes. While EA was a potent inhibitor of both P450 2E1 and 1A1 activities, P450 3A1/2 activity was not significantly affected by 100 |xM EA. Finally, although oral absorption and bioavailability of EA are variable (50), the in vitro data presented here suggest that if EA is present Rats were fed EA in the diet and hepatic and esophageal cytosols and microsomes were prepared as described in Materials and methods. Enzyme activities were determined as described in Materials and methods. *GST activity is expressed as |imol l-chloro-2,4-dinitrobenzene conjugated/min/mg, NAD(P)H:QR activity is expressed as |imol 2,6-dichloroindophenol reduced/min/mg, UDPGT activity is expressed as nmol 4 nitrophenyl-glucuronide formed/min/mg and mEH activity is expressed as nmol diol product formed from in sufficient concentrations in target organs it may inhibit bioactivation of procarcinogens by specific forms of P450. Mandal and Stoner (9) have demonstrated that the concentration of EA in the esophageal tissue of rats fed a 4 g/kg EA diet, as described here, is ~15 |aM, suggesting that tissue levels in vivo are of the same order of magnitude as the K t values for the inhibition of 1A1 and 2E1 determined here.
The effect of dietary EA on cytochromes P450 in the rat esophageal mucosa was also examined. Barch and Fox had previously demonstrated that dietary EA decreased total esophageal P450s, but they did not determine changes in specific P450s (18). We were not able to determine total P450 content of the rat esophageal mucosal microsomes, since we did not have sufficient quantities of these microsomes available for this measurement Of the forms investigated by Western blot analysis only P450 1A1 could be detected in rat esophageal mucosal microsomes, but EA administration did not affect the level of its expression. Although it is conceivable that EA may inhibit NMBA-induced tumors in the rat esophagus by inhibiting rat esophageal mucosal P450 1A1 activity, we were unable to test this hypothesis, since the limited quantities of esophageal microsomes available did not allow us to perform the EROD assay. However, as noted previously, EA is a potent non-competitive inhibitor of liver 1A1.
Western blots demonstrated that EA administration resulted in a marked decrease in the expression of hepatic mEH. mEH is important both in the bioactivation of the procarcinogen benzo[a]pyrene to the ultimate carcinogen, benzo[a]pyrene 7,8-diol-9,10-epoxide-2 (52), as well as detoxification of other procarcinogens (53) . The decrease in the expression of mEH is of interest, since EA has been shown to inhibit polycyclic aromatic hydrocarbon carcinogenesis (2, 15, (19) (20) (21) (22) . However, in this study dietary EA treatment had no effect on mEH catalytic activity as measured by the metabolism of styrene oxide. Das et al. earlier demonstrated that chronic oral feeding of EA over 16 weeks or acute i.p. administration of EA over 5 days to BALB/c mice did not effect EH activities in liver or lung (11), as we have seen in rat liver. Mukhtar et al. demonstrated that chronic oral feeding of EA to BALB/c mice over 120 days did decrease EH activity in skin (2) . The explanation for the discrepancy between the decrease in mEH expression and lack of change in mEH activity is unclear.
This study also examined the effects of dietary EA on several phase II enzymes in the rat liver and esophageal 826 mucosa. EA increased hepatic GST activity by up to 26%, which agrees with earlier studies (2,11). However, much more significant increases were seen when the activities of specific GSTs were measured, with increases ranging from ~80% (5-5) up to 190% (2-2). These GST isozymes were selected for further study since they are major hepatic forms, are fairly well characterized with regard to substrate preference and they are thought to play important roles in the detoxication of a variety of carcinogens (54) . Form 2-2 is a homodimer thought to act as a non-selenium-dependent GSH peroxidase. Form 4-4 is a homodimeric GST which metabolizes a variety of mutagenic arene oxides. GST 5-5 is also a homodimer and shows very low activity with CDNB. In addition, dietary EA increased hepatic UDPGT and NAD(P)H:QR activities by up to 75 and 17% respectively. The induction of hepatic UDPGT activity was one of the most significant changes seen in any of the drug metabolizing enzymes tested in this study. The UDPGTs are a superfamily of enzymes which catalyze glucuronidation of various xenobiotics and endogenous compounds in most tissues (55) . A significant decrease in GST form 2-2 (66%) was observed in rat esophagus. Other than that change, no other significant changes were observed in GST or NAD(P)H:QR activities in the rat esophageal mucosal cytosol. Therefore, dietary EA appears to have a more profound effect on the activities of phase II enzymes than phase I enzymes. Also, its effects on phase II enzymes exhibit some tissue specificity. The significant induction of several phase II enzymes in the liver may play an important role in the ability of EA to protect the liver against hepatotoxins and carcinogens metabolized by these enzymes.
In conclusion, EA is a broad chemopreventive agent which may exert its anticarcinogenic effects by several mechanisms. EA inhibits hepatic cytochrome P450 1A1 and 2E1 in a noncompetitive manner. EA also induces some hepatic phase II enzymes. In this study there was no effect of EA on the P450s of the esophageal mucosa, but it did have significant effects on some esophageal GSTs. Since EA appears to only induce phase II enzymes and not P450s, EA may be a monofunctional anticarcinogenic enzyme inducer (56) . These results may explain in part the chemoprotective properties of EA towards several carcinogens. Finally, its ability to act as a potent inhibitor of some forms of P450 may also be an important aspect of its chemoprotective activity.
